Online inquiry

IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7288MR)

This product GTTS-WQ7288MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CSF1R gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001288705.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1436
UniProt ID P07333
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7288MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3269MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ART621
GTTS-WQ1283MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ890MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ8661MR IVTScrip™ mRNA-Anti-CD38, HuMax-CD38(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-CD38
GTTS-WQ1865MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGEN1884
GTTS-WQ11672MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ3122MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ9041MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-18F1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW